Increased risk of new-onset diabetes observed in children following COVID-19 infection: Study

The electronic health records obtained through TriNetX analytics platforms from January 1, 2020, to December 31, 2022, were utilized in this retrospective cohort research. Children without diabetes who were between the ages of 10 and 19 were included. Data analysis was carried out from August 15 to September 15, 2023, with further studies conducted in January 20 and August 8 to 13, 2024. The primary exposure was a diagnosis of COVID-19 or a respiratory illness that was not COVID-19. The main result was the comparison of new T2D diagnoses at 1, 3, and 6 months following index infection by risk ratios (RRs) and 95% confidence intervals (CIs).

After propensity score matching, a total of 3,06,801 patients with COVID-19 and 3,06,801 patients with other respiratory infections (ORIs) but no reported COVID-19 were included in the primary research group, which comprised 6,13,602 individuals. When compared to the matched group with ORIs, the risk of receiving a new diagnosis of T2D was substantially higher from the day of infection to 1, 3, and 6 months following COVID-19 diagnosis. The hospitalized group and the subpopulation categorized as overweight or obese had similar outcomes. Overall, the pediatric patients aged 10 to 19 years had a higher likelihood of a new T2D diagnosis following COVID-19 infection than other children with ORIs.

Source:

Miller, M. G., Terebuh, P., Kaelber, D. C., Xu, R., & Davis, P. B. (2024). SARS-CoV-2 Infection and New-Onset Type 2 Diabetes Among Pediatric Patients, 2020 to 2022. In JAMA Network Open (Vol. 7, Issue 10, p. e2439444). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2024.39444